Abstract:

Objective   To study the effect of low-dose aspirin on the pre-eclamptic mouse model, and explore the lowest dose and best time for using aspirin to prevent preeclampsia. Methods    To establish the pre-eclamptic mouse model, mice were injected with phosphatidylserine/phosphatidylcholine microvesicles in tail veins from days 5 to 16 of pregnancy. From days 5 to 16 (groups M0, M1,M2 and M3)or days 10 to 16(groups m0, m1, m2 and m3), mice were given saline (M0 and m0), or aspirin at 0.13mg/d (M1 and m1), 0.27mg/d (M2 and m2) and 0.53mg/d (M3 and m3). Systolic blood pressure (SBP) and 24h proteinuria were measured. The weights of the placenta and fetus, and the number of fetuses were evaluated. The placental fibrin deposition area was detected using immunohistochemistry. Results   ①Compared with the controls, the mice given saline(M0 or m0) showed a significant elevation in SBP, a decrease in proteinuria and a more diffuse fibrin deposition area(P<0.05). ②In all above markers, M2 and M3 had significant differences compared with M0(P<0.05), while there was no significant difference between M2 and M3(P>0.05). ③There was no significant difference among the mice given aspirin from days 10 to 16 of pregnancy (m1, m2 and m3) (P>0.05). Conclusion   Using aspirin at 0.27mg/d(about 100mg/d for human) from day 5 of preg-nancy can improve placental blood circulation in the pre-eclamptic mouse model, decrease the formation of microthrombus, and benefit the mother and fetus.

Key words: Preeclampsia; Aspirin; Disease model; Mice